Motesanib Diphosphate

N/A

Report date: 2025/12/08 17:18:46
NME

Base Information

Drug NameMotesanib Diphosphate
Drug Alias Name二磷酸莫替沙尼motesanib莫替沙尼二磷酸盐motesanibum莫替沙尼 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPlatelet-derived growth factor receptor inhibitorsVascular endothelial growth factor receptor 3 antagonistsVascular endothelial growth factor receptor 1 antagonists +[6] 
TargetsVascular endothelial growth factor receptor 2Tyrosine-protein kinase receptor RETVascular endothelial growth factor receptor 1 +[6] 
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursLymphoproliferative Disorders +[20] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSidney Kimmel Cancer Center At Thomas Jefferson UniversityNational Cancer InstituteAmgen Inc +[4] 
Active IndicationsN/A
Inactive IndicationsMetastatic breast cancerSolid tumoursLymphoproliferative Disorders +[20] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG